LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX)

Historical Holders from Q1 2021 to Q3 2025

Type / Class
Equity / Common shares, Euro 0.12 nominal value per share
Symbol
LVTX
Shares outstanding
26,019,256
Price per share
$1.56
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
10,325,473
Holdings value
$16,107,942
% of all portfolios
0%
Share change
+2,320,542
Value change
+$3,784,171
Average buys %
+0%
Average sells %
-0%
Number of holders
21
Price from insider filings
$1.51
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Shay Capital LLC 9.9% $3,972,497 2,596,403 Shay Capital LLC 19 Sep 2025
BML Investment Partners, L.P. 7.4% $2,447,638 1,958,110 BML Investment Partners, L.P. 26 Feb 2025
Cooperatieve Gilde Healthcare IV U.A. 3.9% -66% $1,561,194 -$2,973,967 1,014,751 -66% Cooperatieve Gilde Healthcare IV U.A. 20 Oct 2025
As of 30 Sep 2025, LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) has 21 institutional shareholders filing 13F forms. They hold 10,325,473 shares of 26,019,256 outstanding shares (40%) .

Top 25 institutional shareholders own 40% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
Shay Capital LLC 9.8% 2,548,730 0.72% $3,976,019
Redmile Group, LLC 8% 2,074,372 0% 0.31% $3,236,020
BML Capital Management, LLC 7.6% 1,970,610 0% 2.8% $3,074,152
Sanofi 7.4% 1,919,455 0% 1.2% $2,994,350
Merck & Co., Inc. 4.4% 1,149,345 0% 0.79% $1,792,978
GTS SECURITIES LLC 0.77% 200,000 0.01% $312,000
Rangeley Capital, LLC 0.63% 165,000 +509% 0.25% $257,400
PNC Financial Services Group, Inc. 0.25% 65,000 0% 0% $101,400
CITADEL ADVISORS LLC 0.2% 53,308 +2.9% 0% $83,160
ROYAL BANK OF CANADA 0.17% 44,348 0% $69,000
Lepercq De Neuflize Asset Management LLC 0.12% 31,000 0% 0.03% $48,360
JBF Capital, Inc. 0.09% 23,911 0.01% $37,301
XTX Topco Ltd 0.08% 21,727 0% $33,894
UBS Group AG 0.06% 15,871 -3.1% 0% $24,759
TORNO CAPITAL, LLC 0.06% 15,000 0.01% $23,400
GEODE CAPITAL MANAGEMENT, LLC 0.05% 14,170 0% 0% $22,105
EQUITEC PROPRIETARY MARKETS, LLC 0.05% 12,500 0.12% $19,500
JONES FINANCIAL COMPANIES LLLP 0% 400 0% 0% $636
TSFG, LLC 0% 400 0% 0% $1,000
SBI Securities Co., Ltd. 0% 300 0% 0% $468
Smallwood Wealth Investment Management, LLC 0% 26 0% $40
TWO SIGMA INVESTMENTS, LP 0% 0 -100% $0
Bruce & Co., Inc. 0% 0 -100% $0
MORGAN STANLEY 0% 0 -100% $0
Pathway Financial Advisors LLC 0% 0 -100% $0

Institutional Holders of LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 10,325,473 $16,107,942 +$3,784,171 $1.56 21
2025 Q2 8,051,831 $10,628,889 -$2,392 $1.32 19
2025 Q1 8,044,890 $10,217,501 +$2,034,482 $1.27 20
2024 Q4 6,472,867 $6,154,436 -$431,785 $0.9510 21
2024 Q3 3,608,399 $5,990,569 -$252,767 $1.66 20
2024 Q2 3,758,209 $6,765,357 -$68,179 $1.80 19
2024 Q1 3,760,671 $12,522,082 +$2,293,553 $3.33 21
2023 Q4 400 $1,000 $0 $2.04 2
2023 Q3 400 $1,000 -$23,000 $2.00 2
2023 Q2 5,746,005 $11,663,321 -$1,820,220 $2.03 15
2023 Q1 6,739,020 $11,187,178 -$1,098,483 $1.66 18
2022 Q4 7,365,727 $25,779,313 -$425,661 $3.50 17
2022 Q3 7,452,823 $34,059,026 -$58,919 $4.57 12
2022 Q2 7,839,304 $22,812,045 -$450,028 $2.95 16
2022 Q1 7,995,442 $35,178,298 -$409,463 $4.40 16
2021 Q4 8,054,131 $44,296,000 -$912,124 $5.50 18
2021 Q3 8,217,728 $48,648,000 -$5,131,857 $5.92 17
2021 Q2 8,772,945 $95,450,000 -$2,957,983 $10.88 18
2021 Q1 9,222,819 $139,085,000 +$139,084,952 $15.19 24